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Objectives: A model that uses right hind-limb unloading of rats is used to study the conse-
quences of skeletal unloading during various conditions like space ﬂights and prolonged
bed  rest in elderly. This study was aimed to investigate the additive effects of antiresorptive
agent zoledronic acid (ZOL), alone and in combination with propranolol (PRO) in a rat model
of  disuse osteoporosis.
Methods: In the present study, 3-month-old male Wistar rats had their right hind-limb immo-
bilized (RHLI) for 10 weeks to induce osteopenia, then were randomized into four groups:
(1)  RHLI positive control, (2) RHLI plus ZOL (50 g/kg, i.v. single dose), (3) RHLI plus PRO
(0.1 mg/kg, s.c. 5 days per week), (4) RHLI plus PRO (0.1 mg/kg, s.c. 5 days per week) plus ZOL
(50  g/kg, i.v. single dose) for another 10 weeks. One group of non-immobilized rats was used
as  negative control. At the end of treatment, the femurs were removed and tested for bone
porosity, bone mechanical properties, and bone dry and ash weight.
Results: With respect to improvement in the mechanical strength of the femoral mid-
shaft, the combination treatment with ZOL plus PRO was more effective than ZOL or PRO
monotherapy. Moreover, combination therapy using ZOL plus PRO was more effective in
improving dry bone weight and preserved the cortical bone porosity better than monother-
apy  using ZOL or PRO in RHLI rats.
Conclusions: These data suggest that this combined treatment with ZOL plus PRO should berecommended for the treatment of disuse osteoporosis.
© 2014 Elsevier Editora Ltda. All rights reserved.∗ Corresponding author.
E-mail: deepak kumarkhajuria@yahoo.co.in (D.K. Khajuria).
ttp://dx.doi.org/10.1016/j.rbre.2014.07.007
255-5021/© 2014 Elsevier Editora Ltda. All rights reserved.
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Efeitos  da  terapia  combinada  com  ácido  zoledrônico  e  propranolol  na
resistência  mecânica  em  um  modelo  de  rato  com  osteoporose  por  desuso
Palavras-chave:
Osteoporose por desuso
Estudo com ratos
Ácido zoledrônico
Propranolol
r  e  s  u  m  o
Objetivos: Investigar os efeitos aditivos do agente antirreabsorc¸ão ácido zoledrônico (ZOL),
isolado e em combinac¸ão ao propranolol (PRO), em um modelo de rato com osteoporose por
desuso.
Métodos: Usou-se um modelo de pata traseira direita de rato privada de descarga de peso
para estudar as consequências da falta de descarga de peso sobre o esqueleto durante várias
condic¸ões, como missões espaciais e repouso prolongado no leito em idosos. Ratos Wistar
machos de três meses de idade foram submetidos à imobilizac¸ão da pata traseira direita
(IPTD) por 10 semanas para induzir à osteopenia; em seguida, foram divididos aleatoria-
mente em quatro grupos: 1 – IPTD para controle positivo; 2 – IPTD mais ZOL (50 g/kg, dose
única intravenosa); 3 – IPTD mais PRO (0,1 mg/kg, via subcutnea, cinco dias na semana); 4
–  IPTD mais PRO (0,1 mg/kg, via subcutnea, cinco dias na semana) mais ZOL (50 g/kg, dose
única intravenosa) por outras 10 semanas. Um grupo de ratos não imobilizados foi usado
como controle negativo. No ﬁm do tratamento, os fêmures foram removidos e testaram-se
a  porosidade do osso e suas propriedades mecnicas, além do peso seco e das cinzas do osso.
Resultados: No que diz respeito à melhoria da resistência mecnica da diáﬁse femoral média,
a  terapia combinada com ZOL mais PRO foi mais eﬁcaz do que a monoterapia com ZOL ou
PRO.  Além disso, a terapia combinada com ZOL mais PRO foi mais eﬁcaz na melhoria do
peso seco do osso e preservou melhor a porosidade do osso cortical do que a monoterapia
com ZOL ou PRO em ratos submetidos à imobilizac¸ão da pata traseira direita.
Conclusões: Esses dados sugerem que a terapia combinada com ZOL mais PRO deve ser
recomendada para o tratamento da osteoporose por desuso.
©  2014 Elsevier Editora Ltda. Todos os direitos reservados.Introduction
Osteoporosis is a bone debilitating disease that causes nearly
9 million bone fractures each year.1 Disuse (unloading) is one
of the important causes of osteoporosis.2 Mechanical load-
ing is essential for the normal functioning of bone tissue.
Immobilization results in imbalance of bone metabolism fol-
lowed by rapid bone loss and impairment of bone mechanical
function.3 This immobilization-induced bone loss is caused
by an increased bone resorption and a decreased bone forma-
tion. Disuse (unloading) osteoporosis occurs in patients with
spinal cord injuries, patients conﬁned to prolonged bed rest,
and astronauts exposed to microgravity during space ﬂight.2
Microgravity induced osteoporosis poses a major threat to
the astronaut’s health. Microgravity leads to the unloading of
the skeleton especially weight bearing bones.3 Disuse osteo-
porosis not only increases the susceptibility to fractures in
patients with spinal cord injuries and elderly requiring bed
rest, but also threatens safety and health of astronauts dur-
ing spaceﬂights. Therefore, it is very essential to ﬁnd relevant
countermeasures for disuse osteoporosis to reduce or prevent
such bone loss.
Several animal models have been suggested for studying
immobilization induced bone loss including neurectomy, tail
suspension, plaster casting, and elastic bandaging. In this
study, right hind-limb immobilization (RHLI) was achieved by
a new procedure which was developed to avoid the problems
caused by most widely used methods for the immobiliza-
tion (e.g., plaster cast, bandaging or tail suspension) of rats.The smaller weight of the framework compared with a plas-
ter cast kept the difﬁculty in movement  and locomotion to
a minimum, with a consequent minimal body weight loss
throughout the period of immobilization. Moreover, no skin
ulceration or foot swelling was found in the animals when the
immobilization was removed. The immobilization procedure
proposed was effective in producing long-term disuse in the
hind-limbs of rats and is a good alternative to the traditional
methods of immobilization.2
Zoledronic acid (ZOL) is a third generation nitrogen con-
taining bisphosphonate that binds to hydroxyapatite with
the highest afﬁnity and inhibits osteoclasts with the high-
est potency of all licensed bisphosphonates.4,5 Therefore, ZOL
needs only to be injected once annually in patients, while still
efﬁciently inhibiting osteoclastic activity and thereby reduc-
ing the risk of fracture.6 Although anti-resorptive agents such
as bisphosphonates are effective in reducing bone loss, they
are not able to induce formation of a new one.5
Propranolol (PRO), a non-selective -adrenergic antagonist,
is now considered to be a potential drug under investiga-
tion for fracture healing and more  speciﬁcally for osteoporosis
therapy. In rat model of postmenopausal osteoporosis treat-
ment with PRO improves bone properties by increasing bone
formation and decreasing bone resorption.7–10 Moreover, var-
ious preclinical studies have demonstrated that treatment
by PRO mitigated the bone loss induced by unloading.2,11,12
Furthermore, results of some prior epidemiological studies
conﬁrm the hypothesis that -blockers use is associated with a
decrease in fracture risk.13–15 Combination therapy is now the
subject of extensive investigation because, in some cases, it
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an increase the effectiveness of treatment. Teriparatide is an
nalog of human parathyroid hormone (PTH). It is an anabolic
gent that reduces the risk of fracture in osteoporotic patients.
ombined PTH and bisphosphonate treatment resulted in
ore  pronounced improvements of the bone architecture
han either PTH or bisphosphonate treatment alone.16–18
odrigues et al. demonstrated that low doses of PRO suppress
one resorption by inhibiting receptor activator of nuclear
actor kappa-B ligand (RANKL)-mediated osteoclastogenesis
s well as inﬂammatory markers without affecting hemody-
amic parameters.19 This result is supported by a previous
nding, which showed that propranolol stimulates osteopro-
egerin (OPG) on its own in osteoblast cells.20 The ability to
timulate osteoblast, while also damping osteoclasts makes
RO an attractive and unique alternative to antiresorptive
herapy for osteoporosis. PRO, which could directly prevent
one loss and biomechanical alteration by increasing bone
ormation and decreasing bone resorption, may be the next
nabolic agent for osteoporosis treatment after PTH.7,8,10,19,20
As immobilization induced bone loss involves both
ncreased bone resorption and decreased bone formation, it
eems to be obvious to target the immobilization induced
one loss with a combined antiresorptive and bone anabolic
reatment regimen, such as ZOL and PRO. The effects of a com-
ined PRO and ZOL treatment have previously been studied
n ovariectomized rats,7 whereas this treatment regimen has
ot previously been investigated in immobilization-induced
steopenia. Consequently, the aim of the present study was
o investigate the efﬁcacy of a bone anabolic agent PRO, a
one antiresorptive agent ZOL, and the combination of these
wo in the treatment of immobilization-induced osteope-
ia in rats. Owing to the different mechanisms of action of
OL and PRO, our hypothesis was that the combination of
OL and PRO would facilitate greater improvements in bone
roperties than either intervention alone. We assessed the
arameters as follows: (1) the mechanical properties in immo-
ilized (right) and non-immobilized (left) femoral mid-shaft;
2) the bone porosity measurement of the immobilized (right)
nd non-immobilized (left) femur;(3) measurement of immo-
ilized (right) and non-immobilized (left) dry bone and ash
eight.
aterials  and  methods
rugs,  chemicals  and  other  materials
OL was obtained from Naprod Life Sciences, Maharashtra,
ndia. PRO, ketamine, xylazine and xylene was obtained from
urobindo Pharma (Hyderabad, India), Neon Pharma (Mum-
ai, India), Indian Immunologicals (Hyderabad, India), and S.D.
ine chemicals (Mumbai, India), respectively.
xperimental  animals
n-house laboratory bred healthy male Wistar rats with 12
eeks of age were included in the study. Animals were
aintained under controlled temperature at 25 ± 2 ◦C with
2 h light/dark cycle with food and water and provided ad
ibitum. The experiments were conducted as per the CPCSEA 5;5 5(6):501–511 503
(Committee for the Purpose of Control and Supervision of
Experiments on Animals) guidelines after obtaining ethical
clearance from the Institutional Animal Ethical Committee.
Pre-clinical  study  design
At three months of age, right hind-limb of the rats were
immobilized against the abdomen under ketamine (80 mg/kg)
and xylazine (10 mg/kg) anesthesia, intraperitoneally accord-
ing to a new method of right hind-limb immobilization (RHLI)
described previously.2
Rats were divided into 5 groups (6 rats per group): (1)
non-immobilized (negative control) group; (2) RHLI (positive
control) for 20 weeks; (3) RHLI for 10 weeks, and then RHLI plus
ZOL (50 g/kg, single intravenous dose) for another 10 weeks;
(4) RHLI for 10 weeks, and then RHLI plus PRO (0.1 mg/kg,
injected subcutaneously 5 days per week) for another 10
weeks; (5) RHLI for 10 weeks, then RHLI plus PRO (0.1 mg/kg,
injected subcutaneously 5 days per week) plus ZOL (50 g/kg,
single intravenous dose) for another 10 weeks. Subcutaneous
injections ﬁve days per week in case of immobilized groups
treated with PRO and ZOL plus PRO require some animal
handling and create some stress to the animals. Therefore,
non-immobilized (negative control) and RHLI (positive control)
and RHLI plus ZOL groups were subcutaneously adminis-
tered vehicle (normal saline, 5 days/week) for 10 weeks. The
medication dosages used in this experiment were selected
from previous studies on rat on rat model of postmenopausal
osteoporosis.7 At the end of treatment study, all groups were
euthanized by an overdose of anesthesia. In all rats, immo-
bilized (right) and non-immobilized (left) were excised and
cleared of fat and connective tissues. Femurs were soaked in
saline solution gauze and frozen at −20 ◦C till further analysis.
Both immobilized (right) and non-immobilized (left) femurs
were used for measurement of bone porosity, biomechanical
properties, femoral length, femoral dry weight and ash weight.
Final  body  weight  and  femoral  length
Body weight (expressed in grams) was monitored at the start
and the end of the experiments. Femoral length was measured
with a precision caliper.
Measurement  of  bone  porosity  by  X-ray  imaging
The right femurs of all animals were scanned with foX-Rayzor,
which is a portable X-ray inspection system equipped with
“Calculate histogram” tool software, according to the method
described by previously.8,21 Brieﬂy, for X-ray analysis of rat
femur, whole femur was divided into four equal ﬁelds, which
includes distal femoral epiphysis (R1), femoral shaft (R2 and
R3) and proximal femur (R4).
Biomechanical  bone  strength  testingThe mechanical properties of the femoral mid-shaft were
measured using three-point bending, using a universal test-
ing machine (BISS Makron, Bangalore, India). Femur strength
was assessed by three-point bending as previouslydescribed.8
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Table 1 – Effects of the different treatments on body weight.
Body weight
Group Pre-treatment (g) Post-treatment (g)
Normal control 253.2 ± 10.65a 320.1 ± 13.39a
RHLI positive control 230.1 ± 18.22 216.6  ± 9.01
RHLI + ZOL 229.4 ± 11.22 218.0 ± 10.19
RHLI + PRO 222.4 ± 11.07 217.0 ± 10.21
RHLI + ZOL + PRO 227.4 ± 19.88 219.6 ± 14.14
Pre-treatment shows the data on the day prior to the start of treatment. Post-treatment shows data on the ﬁnal day of the treatment. Data are
expressed as the mean ± S.D. (n = 6), evaluated by one-way ANOVA followed by Tukey’s multiple comparison test.
ept no
signiﬁcantly higher than those for the non-immobilized nor-a p < 0.001, compared to RHLI (positive control) group. All groups exc
Brieﬂy, femurs were removed from the −20 ◦C freezer and
rehydrated in a saline solution for 4 h at room temperature.
Hydrated weight of the bones was determined using a four
decimal place digital scale. Length of the bones was measured
with calipers. Specimens were placed on two supports that
were separated by a distance of 12 mm and bent until frac-
ture by lowering the crosshead positioned at the mid-shaft at
a constant speed of 0.033 mm/s. From the load-displacement
curve, the peak load (N), the ultimate stiffness (N/mm), and the
toughness (mJ) were obtained. Ultimate stress (strength) and
Young’s modulus were derived from load-deformation curves
obtained by using equations described by Khajuria et al.8
Measurement  of  femoral  dry  weight  and  ash  weight
After conducting three-point bending test, the femurs of all
animals were dehydrated with ethanol, and fat was removed
with diethyl ether. After the bones were allowed to air-dry,
the dry bone weight was measured with a digital weighing
balance. Next, the dried femurs were burned to ash at 900 ◦C
for 5 h, and their ash weight was measured.
Statistical  analysis
All data were expressed as the mean ± standard deviation
(SD). For all the data, comparisons between different treat-
ments were analyzed by one-way ANOVA followed by Tukey’s
multiple comparison tests, and differences between the
immobilized side and the non-immobilized side were com-
pared with the Wilcoxon signed-rank test. In all cases, a
probability error of less than 0.05 was selected as the criterion
Table 2 – Average femoral length in control and experimental g
Group Left (non-imm
Normal control 40.80 ± 2.1 
RHLI positive control 39.99 ± 3.4 
RHLI + ZOL 40.31 ± 4.7 
RHLI + PRO 40.23 ± 3.3 
RHLI + ZOL + PRO 40.51 ± 7.6 
Data are expressed as the mean ± S.D. (n = 6). All groups except normal grormal group underwent right hind-limb immobilization (RHLI).
for statistical signiﬁcance. Graphs were drawn using Graph
Pad Prism (version 5.0 for Windows).
Results
Effect  of  different  treatments  on  body  weight  and  femoral
length
Ten weeks after RHLI, the body weights were signiﬁcantly
lower for animals in the RHLI (positive control) and RHLI
treatment groups compared with the non-immobilized nor-
mal  group. This difference became greater at the end of the
experiment (RHLI for another 10 weeks). However, there were
no statistically signiﬁcant differences in weights observed
between any of the active treatment groups and that of the
RHLI (positive control) group (Table 1).
The length of the immobilized femurs was not signiﬁcantly
different from that of the non-immobilized femurs of the same
rats in the RHLI (positive control) group and RHLI treatment
groups (Table 2).
Effect  of  different  treatments  on  bone  porosity
X-ray transmission intensity for the RHLI (positive control)
group at R1, R2, R3 and R4 regions of rat femoral bone wasmal  control group, which indicates an immobilization elicited
increase in porosity in these areas.
After 10 weeks of therapy, all active treatments (single and
combined) succeededin decreasing bone porosity in RHLI rats.
roups of rats.
Femur length (mm)
obilized) Right (immobilized)
41.09 ± 2.2
39.89 ± 1.3
40.23 ± 4.7
40.14 ± 8.7
40.48 ± 2.9
up underwent right hind-limb immobilization (RHLI).
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Fig. 1 – Effect of zoledronic acid and propranolol, alone or in combination on femoral porosity. Data are shown as the
mean ± SD (n = 6), evaluated by Tukey’s multiple comparison test. Bone porosity of R1: distal femoral epiphysis, R2: distal
femoral shaft, R3: proximal femoral shaft, R4: proximal femoral epiphysis *p < 0.05; **p < 0.01; ***p < 0.001, compared to RHLI
(positive control) group; ap < 0.05, compared to ZOL plus PRO group. All groups except normal group underwent right
hind-limb immobilization (RHLI).
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nhe X-ray transmission intensity of ZOL, PRO and ZOL plus
RO groups was signiﬁcantly lower as compared with RHLI
positive control) group at R1, R2, R3 and R4 regions of rat
emoral bone. The X-ray transmission intensity of ZOL plus
RO groups was signiﬁcantly lower than that of the ZOL and
RO group at R1, R2, R3 and R4 regions. These results indi-
ate that as compared to monotherapy with ZOL or PRO, the
ombination therapy with ZOL plus PRO is more beneﬁcial
or the mass of both trabecular and cortical bones that were
ecreased by immobilization (Fig. 1).
ffect  of  different  treatments  on  mechanical  properties  in
he femoral  mid-shaft
ig. 2 shows the peak load, ultimate stiffness, toughness, ulti-
ate strength and Young’s modulus in the femoral mid-shaft,
espectively. Three-point bending tests of the right femur indi-
ated that RHLI (positive control) group caused signiﬁcant
eductions in the peak load, ultimate stiffness, toughness,
ltimate strength and Young’s modulus compared with those
n non-immobilized normal group. In the ZOL, PRO and ZOL
lus PRO groups, the peak load, ultimate stiffness, tough-
ess, ultimate strength and Young’s modulus of the femur wassigniﬁcantly higher than in the RHLI (positive control) group. In
ZOL and PRO groups, the ultimate strength and Young’s mod-
ulus was signiﬁcantly lower than that in the ZOL plus PRO
group.
Comparison  between  non-immobilized  (left)  leg  and
immobilized  (right)  leg  within  a  same  group
RHLI induced a signiﬁcant decrease in dry and ash weights
in RHLI (positive control) rat femurs compared to non-
immobilized normal control rats (Table 3). In the RHLI rats
treated with all active treatments (single and combined), dry
and ash weights were signiﬁcantly heavier than those in the
RHLI (positive control) group. The RHLI femur of the rats
treated with ZOL plus PRO, the dry and ash weight was sig-
niﬁcantly heavier than those in ZOL or PRO treated groups.
In the left non-immobilized femurs, no signiﬁcant difference
was observed between RHLI (positive control) group, non-
immobilized normal group and all active treatments (single
and combined) groups.
The bone porosity and mechanical properties of the left and
right legs are plotted as “split-bar” diagrams in Figs. 3 and 4,
respectively. An asterisk indicates that there was a
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Fig. 2 – Effects of zoledronic acid, propranolol, or zoledronic acid plus propranolol on the mechanical strength of the femoral
diaphysis. The diaphysis was subjected to three-point bending to failure, which provided data on peak load (a), ultimate
stiffness (b), toughness (c), ultimate strength (d), and Young’s modulus (e). Data are shown as the mean ± SD (n = 6),
evaluated by Tukey’s multiple comparison test. *p < 0.05; **p < 0.01; ***p < 0.001, compared to RHLI (positive control) group;
ap < 0.05, compared to ZOL + PRO group. All groups except normal group underwent right hind-limb immobilization (RHLI).
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Fig. 3 – Femoral porosity for the non-immobilized (left bar) and the immobilized (right bar) side with in the same group.
Asterisk denotes signiﬁcant difference between the non-immobilized side and the immobilized side (mean ± SD). All groups
except normal control group underwent right hind-limb immobilization (RHLI).
s
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gigniﬁcant difference between the left and right leg within
he same group. At R1, R2, R3 and R4 regions of rat femoral
one, the X-ray transmission intensity for the immobilized
ide (right) seemed signiﬁcantly higher than those from the
on-immobilized side (left) in the RHLI (positive control)
roup.
Table 3 – Effect of immobilization and different treatments on d
Left non-immobilized femur 
Group Dry bone weight
(mg/bone)
Bone ash 
(mg/bo
Normal control 630.7 ± 8.1 381.4 ± 7.
RHLI positive control 620.5 ± 10.9 368.9 ± 4.
RHLI + ZOL 622.1 ± 18.1 379.1 ± 7.
RHLI + PRO 619.3 ± 12.5 372.9 ± 8.
RHLI + ZOL + PRO 638.2 ± 9.2 388.9 ± 15
Data are expressed as the mean ± S.D. (n = 6), evaluated by one-way ANOVA
a Indicates, for the parameter, a signiﬁcant difference of the active treatm
b p < 0.05.
c p < 0.001, compared to RHLI (positive control) group;
d p < 0.05 compared to ZOL plus PRO group. All groups except normal grou
e p < 0.01.Similarly, at R1, R2, R3 and R4 regions, the X-ray trans-
mission intensity for the immobilized side (right) seemed
signiﬁcantly higher than those from the non-immobilized side
(left) in the immobilized groups treated with ZOL or PRO. In
contrast, the RHLI group treated with ZOL plus PRO showed
full protection against disuse osteoporosis at R1, R2, R3 and
ry bone and ash weight.
Right immobilized femur
weight
ne)
Dry  bone weight
(mg/bone)a
Bone ash weight
(mg/bone)b
7 639.8 ± 12.2c 385.7 ± 9.4c
3 543.9 ± 15.5 321.5 ± 11.5
2 593.7 ± 13.7c,d 351.7 ± 9.8b,d
5 592.4 ± 12.3c,d 346.1 ± 12.3b,d
.6 617.9 ± 15.5c 365.6 ± 6.2e
 followed by Tukey’s multiple comparison test.
ents between the two legs.
p underwent right hind-limb immobilization (RHLI).
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Fig. 4 – Mechanical properties for the non-immobilized (left bar) and the immobilized (right bar) side with in the same
group. The femoral mid-shaft was subjected to three-point bending to failure, which provided data on peak load (a),
ultimate stiffness (b), toughness (c), ultimate strength (d), and Young’s modulus (e). Asterisk denotes signiﬁcant difference
between the non-immobilized side and the immobilized side (mean ± SD). All groups except normal group underwent right
hind-limb immobilization (RHLI).
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4 regions, as indicated by X-ray transmission intensity values
Fig. 3).
At the femoral mid-diaphysis (three-point bending test),
he effect of immobilization was very pronounced in RHLI
positive control) group; that is, the immobilized side
right) had signiﬁcantly lower values of strength parameters
ncluding peak load, ultimate stiffness, fracture toughness,
ltimate strength and Young’s modulus than the non-
mmobilized side (left). Similarly, in the RHLI groups treated
ith ZOL or PRO, the immobilized side (right) had sig-
iﬁcantly lower values of strength parameters, including
eak load, ultimate stiffness, fracture toughness, ultimate
trength and Young’s modulus than the non-immobilized
ide (left). In contrast, the RHLI group treated with ZOL
lus PRO showed full protection against immobilization
Fig. 4).
iscussion
his study was aimed at clinical application of the combi-
ation therapy with ZOL plus PRO as a curative treatment
f established disuse osteoporosis. Due to the difﬁculty and
igh cost of conducting experiments during a space ﬂight on
stronauts, a number of in vivo ground-based experimental
odels have been established by researchers to simulate the
onditions experienced during a space mission. The present
tudy showed that PRO and ZOL monotherapy was able to
ounteract the bone loss in a rat model of disuse osteo-
orosis. Furthermore, this study showed that combination
herapy with ZOL plus PRO had a therapeutic advantage over
OL or PRO monotherapy for treatment of disuse osteoporo-
is.
Body weight in the normal group was greater than in
he RHLI (positive control) group. This may have been due
o the anesthesia administered during the RHLI procedure.
educed eating and overall reduced mobility are other pos-
ible factors that may have contributed in a minor way to
he development of lower body weight and bone loss. Ear-
ier studies have shown a similar decrease in body weight
fter RHLI.2,22,23 The length of the femur of the immobilized
imb was not signiﬁcantly different from that of the non-
mmobilized intact femur of the same rat, suggesting that
he longitudinal growth of the bone is not retarded in these
nimals. It is therefore more  likely that we  are here dealing
ith immobilization osteoporosis rather than simple growth
etardation.
The increase in the bone porosity at R1, R2, R3, R4 regions
f rat femoral bone, due to unloading of right hind-limb
as suppressed by all active treatments (single and com-
ined). Moreover, the bone porosity of the ZOL plus PRO
roup at R1, R2, R3 and R4 regions of rat femoral bone was
igniﬁcantly lower than that of the ZOL or PRO monother-
py. This indicates that combination therapy with ZOL plus
RO thickens and strengthens cortical bone. It is interesting
hat, in animals treated with single and combined therapy,
ry and ash weights in the right immobilized femur were
igniﬁcantly greater than those of the RHLI (positive con-
rol) group. Moreover, in the animals treated with combined
herapy of ZOL plus PRO, dry and ash weights in the right 5;5 5(6):501–511 509
immobilized femur were signiﬁcantly greater than those of
the ZOL or PRO groups. These results showed that the com-
bined treatment with ZOL plus PRO is beneﬁcial for increasing
the mass of rat femoral bones that was decreased due to
RHLI.
Mechanical load is crucial for the maintenance of bone
strength. The bone strength is determined by the bone mass
and the intrinsic properties of the bone material. Physical
inactivity due to spinal cord injuries, prolonged bed rest in
elderly and astronauts exposed to microgravity during space
ﬂight would accelerate the bone microarchitecture deteriora-
tion and demineralization.2,7 Combination therapy with ZOL
plus PRO was statistically superior to monotherapy with ZOL
and PRO at increasing femoral mid-shaft toughness and ulti-
mate strength. The current data correlate with ﬁndings from
our previous studies, demonstrating effects of ZOL plus PRO on
the mechanical properties of ovariectomized rat bone.7 There-
fore, it is of high possibility that combination therapy with ZOL
plus PRO is capable of treating/preventing weightlessness-
induced bone loss.
This study has several limitations. It should be noted that
extrapolation to humans of the data from rat studies should
be undertaken with caution because (1) rats are quadrupeds,
and therefore experience a different loading pattern from that
of humans; and (2) the remodeling pattern in rats is different
from that of humans. However, the advantage of using this
preclinical rat model is that it allows assessment not only of
bone turnover and bone mass, but also of bone mechanical
properties.
Comparison made between non-immobilized (left) leg and
immobilized (right) leg within a same group showed that
bone properties were improved by all therapeutic interven-
tions, but the marked osteopenia induced by RHLI were not
completely corrected with single treatments like ZOL or PRO
alone. In contrast, combined treatment with ZOL plus PRO
showed full protection against disuse osteoporosis, suggest-
ing that the combination therapy has a therapeutic advantage
over each monotherapy for the treatment of disuse osteoporo-
sis.
With regard to the clinical situation and the knowledge
gained from the aforementioned studies concerning immobi-
lization and from the present study, it would seem advisable
to shorten immobilization periods as much as possible24,25
and perhaps to consider the use of combination therapy of
ZOL plus PRO as protection against loss of bone density and
strength even during short-term immobilization. Moreover,
the combined therapy with ZOL plus PRO may prevent or
reduce the risk of atrial ﬁbrillation, one of the serious adverse
drug reactions of ZOL.7 In other clinical situations with very
long-term immobilization (paraplegia or tetraplegia, both after
spinal cord lesions, or hemiplegia after cerebrovascular acci-
dent, long term space travel) preventive treatment with ZOL
plus PRO may also be recommended based on ﬁndings of the
present preclinical study.Conclusions
In conclusion, current study provides evidence that PRO and
ZOL, when given as monotherapy, were able to reverse the
 o l . 2
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inhibitory effect of immobilization on bone formation. This
study ﬁrstly demonstrates that combination therapy with
ZOL plus PRO therapy is highly effective in improving the
bone properties in an animal model of disuse osteoporosis,
suggesting that the combination therapy has a therapeutic
advantage over ZOL or PRO monotherapy for the prevention
and treatment of disuse osteoporosis induced by mechani-
cal inactivity. The ﬁndings are consistent with the effects of
ZOL plus PRO on estrogen deﬁciency-induced bone loss and
extend our knowledge regarding the effects of this therapy
in immobilization-induced bone loss. As such, this combined
regimen may be of interest for further evaluation in clinical
studies. Moreover, PRO might be a new potential bone anabolic
agent for prevention/treatment of osteoporosis, and it can
be used either alone or in conjunction with bisphosphonate
drugs.
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